Place · Level 3 · Supplement
Coenzyme Q10 (Ubiquinone / Ubiquinol)
线粒体 ETC 辅基 · Q-SYMBIO 心衰 A 级 · 他汀肌痛 B 级 · 偏头痛 B 级 · 形态 + 剂量真相
Story path
Chapter 1
Q10 · mitochondrial cofactor
Q10 · mitochondrial cofactor
Coenzyme Q10 (CoQ10, ubiquinone) is the cell's key electron shuttle between Complex I → II → III in the mitochondrial electron-transport chain (ETC) + one of the strongest intracellular lipid-soluble antioxidants.
Chemistry:
Benzoquinone ring + 10 isoprenoid side chains (the human form; mice have 9 → hence Q10)Oxidised (ubiquinone) ↔ reduced (ubiquinol) interconversion — the core of its electron-shuttle function
Body sources:
Endogenous synthesis (main): liver + heart + kidney + pancreas → shares the mevalonate pathway with cholesterol synthesisFood: organs (heart / liver / kidney) / sardines / beef / chicken — but < 5 mg/day, far less than endogenous
Why the atlas must cover Q10:
1. Effective for heart failure: Q-SYMBIO 2014 RCT (Mortensen, JACC HF) Level A evidence
2. Statin-induced muscle pain: partial Level B evidence, frequently used clinically
3. Migraine prevention: Level B (Sándor 2005, covered in atlas migraine story)
4. Mitochondrial disease: rare but Q10 is a core treatment
5. Massive anti-ageing marketing: real signal + lots of hype; the atlas debunks
The truth about "statin → ↓ Q10":
Statins inhibit HMG-CoA reductase → block cholesterol synthesisThe upstream of that pathway is also Q10 synthesis → blood Q10 ↓ 16-40% (Päivä 2005)But: the hypothesis "statin lowers Q10 → worsens heart failure" has no RCT evidence"Statin myalgia" may be partly Q10-related — Level B evidence that Q10 reduces myalgia (Banach 2015 meta)
Blood Q10 ≠ tissue Q10:
90% of plasma Q10 is bound to lipoproteins (LDL / HDL)"High blood Q10" often only reflects high blood lipid (lots of LDL)Actual cellular / cardiac / muscle Q10 correlates weakly with plasmaThis is one reason Q10 RCT interpretation is complicated
Chemistry:
Benzoquinone ring + 10 isoprenoid side chains (the human form; mice have 9 → hence Q10)Oxidised (ubiquinone) ↔ reduced (ubiquinol) interconversion — the core of its electron-shuttle function
Body sources:
Endogenous synthesis (main): liver + heart + kidney + pancreas → shares the mevalonate pathway with cholesterol synthesisFood: organs (heart / liver / kidney) / sardines / beef / chicken — but < 5 mg/day, far less than endogenous
Why the atlas must cover Q10:
1. Effective for heart failure: Q-SYMBIO 2014 RCT (Mortensen, JACC HF) Level A evidence
2. Statin-induced muscle pain: partial Level B evidence, frequently used clinically
3. Migraine prevention: Level B (Sándor 2005, covered in atlas migraine story)
4. Mitochondrial disease: rare but Q10 is a core treatment
5. Massive anti-ageing marketing: real signal + lots of hype; the atlas debunks
The truth about "statin → ↓ Q10":
Statins inhibit HMG-CoA reductase → block cholesterol synthesisThe upstream of that pathway is also Q10 synthesis → blood Q10 ↓ 16-40% (Päivä 2005)But: the hypothesis "statin lowers Q10 → worsens heart failure" has no RCT evidence"Statin myalgia" may be partly Q10-related — Level B evidence that Q10 reduces myalgia (Banach 2015 meta)
Blood Q10 ≠ tissue Q10:
90% of plasma Q10 is bound to lipoproteins (LDL / HDL)"High blood Q10" often only reflects high blood lipid (lots of LDL)Actual cellular / cardiac / muscle Q10 correlates weakly with plasmaThis is one reason Q10 RCT interpretation is complicated
Q10 deficiency populations + testing limits
"Measure blood Q10 → decide whether to supplement" is not as simple as it looks. This page unpacks it.Populations genuinely at risk of Q10 deficiency:
1. Older adults (60+)
Endogenous Q10 synthesis falls 10-15% every decadeAt 80, cardiac / liver / kidney Q10 concentrations ≈ 50-60% of values at 20But "do I need to supplement" depends on symptoms, not numbers
2. Long-term statin use (atlas cardiovascular)
Shared mevalonate pathway with cholesterol synthesis → Q10 ↓ 16-40%Not every statin user has muscle pain — most do notSAMS (Statin-Associated Muscle Symptoms) rate: ~ 7-29% (highly variable; placebo-controlled true rate only 1-2%)Q10 supplementation for SAMS has Level B evidence — worth a trial, not mandatory
3. Heart failure (NYHA III-IV)
Myocardial Q10 correlates inversely with HF severityQ-SYMBIO RCT confirmed Q10 supplementation improves hard endpointsThe patients meeting trial-entry criteria gain the most
4. Migraine
Sándor 2005 Neurology RCT: 100-300 mg/day × 3 months → migraine frequency ↓ 50%Atlas migraine trio (Mg + B2 + Q10)
5. Mitochondrial diseases (rare)
MELAS / Leber optic neuropathy / Friedreich ataxia, etc.Neurology / metabolic specialist guidance; Q10 is usually a main treatment (rather than adjunct)
6. Infertility / IVF + advanced age (women 35+)
Bentov 2015 RCT signal: Q10 600 mg/day → improved egg qualitySome fertility centers use empiricallyNot standard IVF protocol, but can be discussed with reproductive specialists
Blood Q10 testing limitations:
Normal range: 0.4-1.5 µg/mL (most labs)Deficiency definition: < 0.5 µg/mLBut:90% of plasma Q10 is bound to LDL/HDL → high LDL → high blood Q10 but not necessarily more tissue Q10Tissue / myocardial Q10 is what mattersPlasma-to-myocardial correlation r ~ 0.3-0.5 (weak-to-moderate)Clinical reality: most clinicians do not measure Q10 levels — empirical supplementation + watch symptom improvementRare mitochondrial disease / deficiency syndromes (severe Q10 deficiency): muscle biopsy → measure muscle Q10
False positives / marketing traps:
"Q10 testing packages" (for healthy people): no indication, numbers have no clinical meaning"All older adults should take Q10": no hard evidence, look at symptoms"Q10 anti-ageing reduces wrinkles": clinical evidence weakReal signals: heart failure + SAMS + migraine prevention + mitochondrial disease
Chapter 2
Q-SYMBIO · HF A-tier
Q-SYMBIO · HF A-tier
The Q-SYMBIO Trial (Mortensen 2014 JACC Heart Failure) — the most important Q10 RCT on the atlas:
Design:
N = 420 moderate-to-severe HF patients (NYHA III-IV) on standard HF therapy100 mg × 3 times/day = 300 mg/day ubiquinone × 2 yearsPrimary endpoint: MACE (CV events + HF worsening + death)
Results:
MACE ↓ 43% (29% vs 15%, p = 0.003)All-cause death ↓ 42% (18% vs 10%, p = 0.018)CV death ↓ 43%Improved NYHA functional classSide effects equivalent to placebo
Why this matters:
Level A (one large RCT + positive hard endpoints) is extremely rare for supplements in cardiology2017 ESC HF guidelines + some US CV societies recommend Q10 as an adjunct for HFDoes not replace first-line ACEi/ARB/β-blocker/SGLT2
Mechanism (proposed):
The myocardium consumes large amounts of adenosine triphosphate: The cell's universal energy currency — almost everything that costs energy spends it. per second — mitochondrial ETC is centralIn HF, myocardial Q10 ↓ + impaired mitochondrial functionSupplemental Q10 → improved cardiac ATP production + antioxidant effect
Follow-up / replication:
Mortensen 2017 follow-up: longer follow-up, same directionMadmani 2014 Cochrane: multi-RCT meta-analysis, HF-improvement signal (large heterogeneity)Controversy: Q-SYMBIO was single-center + industry-funded (Pharma Nord), raising bias concerns; awaiting larger independent replication
Statin-associated muscle symptoms (SAMS):
Banach 2015 meta-analysis (12 RCTs): Q10 ~ 100-300 mg/day → significant SAMS improvementTaylor 2015 GAUSS RCT: negative (no difference for Q10 vs placebo in statin myalgia)Consensus: Level B evidence, some patients benefit; not all SAMS reflects Q10 deficiencyClinical practice: SAMS patients may try Q10 100-200 mg/day × 2-3 months and gauge symptom improvement
Dosing:
HF: 300 mg/day in 3 divided doses (Q-SYMBIO dose)Statin myalgia: 100-200 mg/dayMigraine prevention: 100-300 mg/day (Sándor 2005)General wellness: 100 mg/day (weak evidence, mostly marketing-driven)
Design:
N = 420 moderate-to-severe HF patients (NYHA III-IV) on standard HF therapy100 mg × 3 times/day = 300 mg/day ubiquinone × 2 yearsPrimary endpoint: MACE (CV events + HF worsening + death)
Results:
MACE ↓ 43% (29% vs 15%, p = 0.003)All-cause death ↓ 42% (18% vs 10%, p = 0.018)CV death ↓ 43%Improved NYHA functional classSide effects equivalent to placebo
Why this matters:
Level A (one large RCT + positive hard endpoints) is extremely rare for supplements in cardiology2017 ESC HF guidelines + some US CV societies recommend Q10 as an adjunct for HFDoes not replace first-line ACEi/ARB/β-blocker/SGLT2
Mechanism (proposed):
The myocardium consumes large amounts of adenosine triphosphate: The cell's universal energy currency — almost everything that costs energy spends it. per second — mitochondrial ETC is centralIn HF, myocardial Q10 ↓ + impaired mitochondrial functionSupplemental Q10 → improved cardiac ATP production + antioxidant effect
Follow-up / replication:
Mortensen 2017 follow-up: longer follow-up, same directionMadmani 2014 Cochrane: multi-RCT meta-analysis, HF-improvement signal (large heterogeneity)Controversy: Q-SYMBIO was single-center + industry-funded (Pharma Nord), raising bias concerns; awaiting larger independent replication
Statin-associated muscle symptoms (SAMS):
Banach 2015 meta-analysis (12 RCTs): Q10 ~ 100-300 mg/day → significant SAMS improvementTaylor 2015 GAUSS RCT: negative (no difference for Q10 vs placebo in statin myalgia)Consensus: Level B evidence, some patients benefit; not all SAMS reflects Q10 deficiencyClinical practice: SAMS patients may try Q10 100-200 mg/day × 2-3 months and gauge symptom improvement
Dosing:
HF: 300 mg/day in 3 divided doses (Q-SYMBIO dose)Statin myalgia: 100-200 mg/dayMigraine prevention: 100-300 mg/day (Sándor 2005)General wellness: 100 mg/day (weak evidence, mostly marketing-driven)
Chapter 3
Form + bioavailability
Form + bioavailability
Ubiquinone vs Ubiquinol — which is better?
Ubiquinone (oxidised, traditional):
Cheap ($0.10-0.20 per 100 mg)Most long-term data (most RCTs use this form)Reduced to ubiquinol in the body before actingAbsorption strongly synergised by a fatty meal — < 25% fasting, > 70% with a fatty meal
Ubiquinol (reduced, "active"):
2-4× more expensive ($0.40-0.80 per 100 mg)Claimed bioavailability 3-4× ubiquinone (manufacturer)However: independent RCTs show similar total plasma Q10 rises (both ultimately appear as ubiquinol in blood)Possibly better suited to: older adults / HF / severe oxidative stress (impaired endogenous reduction)Clinical evidence far less than ubiquinone
Conclusion:
Most people: ubiquinone + with a fatty meal = best valueOlder (70+) / HF / high-dose needs: ubiquinol may offer slight advantage, but 1-3× the price is not necessarily worth itDo not pay a premium for "active" marketing — look at measured outcomes (heart rate / myalgia improvement / headache frequency)
Forms:
Softgels (oil-filled): recommended — built-in lipid vehicle, consistent absorptionTablets / powder: must be taken with a fatty meal, otherwise absorption is poor"Water-soluble nano / microcapsule": some high-bioavailability forms, but expensive + clinical difference not always significant
Nutrient / drug interactions:
Vitamin K: both fat-soluble, can be taken togetherWarfarin: Q10 structure resembles vitamin K — may antagonise warfarin, warfarin users must inform their physician + monitor INRAntihypertensives: Q10 may lower BP 5-10 mmHg, monitor if on BP drugsβ-blockers: Q10 may mildly counter their heart-rate-lowering effectChemotherapy: some Q10 + chemotherapy combination studies; discuss with oncology
Ubiquinone (oxidised, traditional):
Cheap ($0.10-0.20 per 100 mg)Most long-term data (most RCTs use this form)Reduced to ubiquinol in the body before actingAbsorption strongly synergised by a fatty meal — < 25% fasting, > 70% with a fatty meal
Ubiquinol (reduced, "active"):
2-4× more expensive ($0.40-0.80 per 100 mg)Claimed bioavailability 3-4× ubiquinone (manufacturer)However: independent RCTs show similar total plasma Q10 rises (both ultimately appear as ubiquinol in blood)Possibly better suited to: older adults / HF / severe oxidative stress (impaired endogenous reduction)Clinical evidence far less than ubiquinone
Conclusion:
Most people: ubiquinone + with a fatty meal = best valueOlder (70+) / HF / high-dose needs: ubiquinol may offer slight advantage, but 1-3× the price is not necessarily worth itDo not pay a premium for "active" marketing — look at measured outcomes (heart rate / myalgia improvement / headache frequency)
Forms:
Softgels (oil-filled): recommended — built-in lipid vehicle, consistent absorptionTablets / powder: must be taken with a fatty meal, otherwise absorption is poor"Water-soluble nano / microcapsule": some high-bioavailability forms, but expensive + clinical difference not always significant
Nutrient / drug interactions:
Vitamin K: both fat-soluble, can be taken togetherWarfarin: Q10 structure resembles vitamin K — may antagonise warfarin, warfarin users must inform their physician + monitor INRAntihypertensives: Q10 may lower BP 5-10 mmHg, monitor if on BP drugsβ-blockers: Q10 may mildly counter their heart-rate-lowering effectChemotherapy: some Q10 + chemotherapy combination studies; discuss with oncology
Chapter 4
Decision tree
Decision tree
Who is Q10 right for?
Level A indications (clear evidence):
Moderate-to-severe heart failure (NYHA II-IV): 300 mg/day (Q-SYMBIO), combined with first-line HF therapyStatin-induced myalgia (SAMS): 100-200 mg/day × 2-3 months trial
Level B indications:
Migraine prevention (one of the atlas migraine trio): 100-300 mg/dayMitochondrial diseases (rare, specialist-guided)Infertility / IVF: some RCT signal, mainly for older-female egg quality (Bentov 2015)
Level C / marketing-driven (weak evidence):
"Anti-ageing / wrinkle reduction""Athletic performance""Fatigue" (except clear mitochondrial disease)"Periodontal disease"
Who should not supplement:
Pregnancy / breastfeeding: lacks dataWarfarin users: monitor INR, discuss with the physicianChildren: only with mitochondrial-disease indication
When to expect effect:
HF / myalgia / migraine: 8-12 weeks before judging; don't quit at 2 weeksPlasma Q10: steady state at 4-6 weeksTrack symptoms in parallel for an objective assessment
Cost-effectiveness:
Ubiquinone 100 mg × 3/day × 1 year ≈ ¥600-1200 (high-quality brand)vs Q-SYMBIO clinical benefit: extremely high ROI in HF patientsvs "wellness" use: not cost-effective
Connections to other atlas stories:
One of the atlas migraine trioalpha-lipoic-acid L4 five-cofactor set (B1/B2/B3/B5 + ALA + Q10 in the mitochondrial series)niacin-b3/nad + riboflavin-b2/flavins L4 (ETC partners)cardiovascular/atherosclerosis L4 (HF context)Statin / dyslipidemia patients: report-rule trigger
Atlas position: Q10 is one of the few supplements on this continent with real hard-endpoint RCT evidence — especially in heart failure. It is not an "anti-ageing miracle pill" but a worthwhile adjunctive therapy in specific indications.
Level A indications (clear evidence):
Moderate-to-severe heart failure (NYHA II-IV): 300 mg/day (Q-SYMBIO), combined with first-line HF therapyStatin-induced myalgia (SAMS): 100-200 mg/day × 2-3 months trial
Level B indications:
Migraine prevention (one of the atlas migraine trio): 100-300 mg/dayMitochondrial diseases (rare, specialist-guided)Infertility / IVF: some RCT signal, mainly for older-female egg quality (Bentov 2015)
Level C / marketing-driven (weak evidence):
"Anti-ageing / wrinkle reduction""Athletic performance""Fatigue" (except clear mitochondrial disease)"Periodontal disease"
Who should not supplement:
Pregnancy / breastfeeding: lacks dataWarfarin users: monitor INR, discuss with the physicianChildren: only with mitochondrial-disease indication
When to expect effect:
HF / myalgia / migraine: 8-12 weeks before judging; don't quit at 2 weeksPlasma Q10: steady state at 4-6 weeksTrack symptoms in parallel for an objective assessment
Cost-effectiveness:
Ubiquinone 100 mg × 3/day × 1 year ≈ ¥600-1200 (high-quality brand)vs Q-SYMBIO clinical benefit: extremely high ROI in HF patientsvs "wellness" use: not cost-effective
Connections to other atlas stories:
One of the atlas migraine trioalpha-lipoic-acid L4 five-cofactor set (B1/B2/B3/B5 + ALA + Q10 in the mitochondrial series)niacin-b3/nad + riboflavin-b2/flavins L4 (ETC partners)cardiovascular/atherosclerosis L4 (HF context)Statin / dyslipidemia patients: report-rule trigger
Atlas position: Q10 is one of the few supplements on this continent with real hard-endpoint RCT evidence — especially in heart failure. It is not an "anti-ageing miracle pill" but a worthwhile adjunctive therapy in specific indications.
Quality testing reality
Q10 is one of the most quality-variable supplement categories — independent testing data are striking.ConsumerLab 2022 testing (40 Q10 products):
17 products (42%) had label content ≠ actual content:5 had content < 80% of label7 had content > 120% of label (overage is also a problem)5 contained no or trace Q10 (i.e., counterfeit)Price + brand name ≠ quality: some famous brands tested poorly, some niche brands tested well
Labdoor 2023 evaluation (top 20 Q10):
Gold tier (90+ points): only 5 — partial models from Doctor's Best, Jarrow, Life Extension, Nature Made, Pure EncapsulationsHeavy-metal testing: 1/3 of products slightly exceeded heavy-metal thresholds (still within FDA safety limits)
Third-party certifications (check before purchase):
USP Verified Mark (US Pharmacopoeia): strictest, tests label + purity + heavy metals + microbesNSF International: similar to USP, common for athletesConsumerLab Approved: independent testing + public reportInformed-Choice / Informed-Sport: doping + purity certification (athlete-grade)Labdoor scoring: independent body, public rankings
Risks of "Taobao / JD Q10":
Domestic OTC Q10 rarely carries third-party certificationRecommendation: look for imported brands with USP or NSF marks (Doctor's Best / Jarrow / Now Foods, etc.), purchase the original via JD International / Tmall InternationalAvoid: 100 capsules under ¥100 (actual cost is well below retail → likely counterfeit / inflated labels)
Dose accuracy:
100 mg label = 40-180 mg measured (ConsumerLab data)Even with a good brand, different batches can varyTest annually across batches if feasible (cautious approach)
Form affects cost:
Ubiquinone 100 mg (standard): $0.10-0.30/capsule (USP-certified)Ubiquinol 100 mg: $0.40-0.80/capsule"Nano" / "water-soluble" enhanced bioavailability: $0.60-1.20/capsuleBest value: USP-certified ubiquinone 100 mg, taken with a fatty meal
When to consider stopping:
Continue (Q10 is doing something):
HF: forever (with HF drugs, lifelong)SAMS improvement: continue while on statinMigraine prevention working: re-evaluate after 6-12 months of maintenance
Consider stopping:
3 months without symptom improvement (SAMS / migraine prevention)Side effects (insomnia / GI discomfort / nausea)Financial pressure + first-line interventions (weight loss + training + diet) take prioritySwitching strategies: e.g., switching from statin to non-statin lipid-lowering (PCSK9 inhibitor) for SAMS → no need for Q10
How to stop:
Stop directly: Q10 has no withdrawal effectObserve for 1-2 months: see if symptoms returnIf symptoms return → restart
Atlas practice: do not pay a premium for "anti-ageing" marketing. True indication + third-party-certified brand + with a fatty meal + 3-6 month assessment = informed use.